Author: Del Pinto, Rita; Ferri, Claudio
Title: The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway Cord-id: p2movnro Document date: 2020_10_12
ID: p2movnro
Snippet: Fabry disease is a progressive, X-linked inherited lysosomal storage disorder where accumulation of glycosphingolipids increases the risk for early cardiovascular complications, including heart failure, stroke, and end stage renal disease. Besides disease-specific therapy, blood pressure (BP) control is of central importance in Fabry disease to reduce disease progression and improve prognosis. Both Fabry disease and hypertension are characterized by the activation of the innate component of the
Document: Fabry disease is a progressive, X-linked inherited lysosomal storage disorder where accumulation of glycosphingolipids increases the risk for early cardiovascular complications, including heart failure, stroke, and end stage renal disease. Besides disease-specific therapy, blood pressure (BP) control is of central importance in Fabry disease to reduce disease progression and improve prognosis. Both Fabry disease and hypertension are characterized by the activation of the innate component of the immune system, with Toll-like receptor 4 (TLR4) as a common trigger to the inflammatory cascade. The renin-angiotensin system (RAS) participates in the establishment of low-grade chronic inflammation and redox unbalance that contribute to organ damage in the long term. Besides exploiting the anti-inflammatory effects of RAS blockade and enzyme replacement therapy, targeted therapies acting on the immune system represent an appealing field of research in these conditions. The aim of this narrative review is to examine the issue of hypertension in the setting of Fabry disease, focusing on the possible determinants of their reciprocal relationship, as well as on the related clinical and therapeutic implications.
Search related documents:
Co phrase search for related documents- ace inhibitor and adaptive immunity: 1
- ace inhibitor and local upregulation: 1
- ace inhibitor and low density: 1, 2
- ace inhibitor and low density lipoprotein: 1, 2
- activity expression and adaptive immunity: 1, 2, 3, 4
- activity expression and adenine dinucleotide phosphate: 1
- activity expression and adhesion molecule: 1, 2, 3, 4, 5, 6
- activity expression and adhesion molecule expression: 1, 2
- activity expression and local upregulation: 1
- activity expression and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activity expression and low density lipoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immunity and adenine dinucleotide phosphate: 1
- adaptive immunity and low density: 1, 2, 3
- adaptive immunity and low grade chronic inflammation: 1, 2, 3, 4, 5
- additional benefit and low density: 1
- adhesion molecule and losartan treatment: 1
- adhesion molecule and low density: 1, 2, 3, 4, 5, 6
- adhesion molecule and low density lipoprotein: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date